Residency · Residency · Child Adolescent Psychiatry
Psychopharmacology for Irritability and Comorbidities in ASD
Overview
No medication treats the core symptoms of ASD — the social communication deficits and restricted, repetitive behaviors that define the disorder. Pharmacotherapy in ASD targets associated symptoms and comorbidities: irritability and aggression, anxiety, ADHD symptoms, sleep disturbance, and self-injurious behavior. Only two medications have FDA approval for irritability in ASD: risperidone (for ages 5 and older) and aripiprazole (for ages 6 and older). Children with ASD tend to be more sensitive to medication side effects and often require lower starting doses and slower titration than neurotypical children. A thorough functional behavioral assessment should always precede or accompany any medication trial for behavioral concerns.
FDA-Approved Medications for Irritability in ASD
Risperidone (Risperdal)
Risperidone received FDA approval for irritability associated with ASD in children ages 5-16. It acts as a dopamine D2 and serotonin 5-HT2A antagonist. The landmark RUPP Autism Network trial (2002) demonstrated a 69% response rate versus 12% for placebo on measures of irritability. It is effective for tantrums, aggression, self-injury, and behavioral rigidity. Dosing starts at 0.25 mg/day for children weighing less than 20 kg or 0.5 mg/day for those over 20 kg, titrating to a range of 0.5-3 mg/day. Onset of effect is often within 1-2 weeks.
The most significant side effect is weight gain — averaging 2.7 kg over 8 weeks in the RUPP trial — which continues with long-term use and can progress to metabolic syndrome with increased glucose, lipids, and insulin resistance. Sedation is common and often dose-limiting. Prolactin elevation is a particular concern with risperidone (the highest among atypical antipsychotics), potentially causing gynecomastia, galactorrhea, and menstrual irregularities. Extrapyramidal symptoms including acute dystonia, akathisia, and rarely tardive dyskinesia can occur. Drooling is particularly common in younger children.
Aripiprazole (Abilify)
Aripiprazole is FDA-approved for irritability in ASD for children ages 6-17. Its mechanism involves partial dopamine D2 agonism, partial 5-HT1A agonism, and 5-HT2A antagonism. Two large RCTs (Marcus et al., 2009; Owen et al., 2009) demonstrated significant improvement in irritability. Dosing starts at 2 mg/day with titration to 5-15 mg/day. Compared to risperidone, aripiprazole may be better tolerated regarding prolactin (it actually lowers prolactin due to its partial agonist properties) and sedation.
Weight gain remains significant but may be slightly less than with risperidone. Sedation is less pronounced. Akathisia and restlessness are more common than with risperidone and can be mistaken for worsening behavioral symptoms — a clinically important distinction. Nausea and vomiting may occur, especially during initiation. Metabolic effects are present but may be less severe than with risperidone.
Choosing Between Risperidone and Aripiprazole
Both medications are effective for irritability, and the choice is typically guided by side effect profile. Risperidone may be preferred when sedation is advantageous (such as when sleep is disrupted) but carries higher prolactin risk. Aripiprazole offers less sedation and lower prolactin risk but a higher risk of akathisia. If one medication fails, the other should be tried before concluding that atypical antipsychotics are ineffective for that patient.
| Feature | Risperidone (Risperdal) | Aripiprazole (Abilify) |
|---|---|---|
| FDA-Approved Ages | 5-16 years | 6-17 years |
| Mechanism | D2 + 5-HT2A antagonist | Partial D2 agonist, partial 5-HT1A agonist, 5-HT2A antagonist |
| Response Rate (RCT) | 69% vs. 12% placebo | Significant improvement in RCTs |
| Starting Dose | 0.25 mg/day (<20 kg); 0.5 mg/day (>20 kg) | 2 mg/day |
| Dose Range | 0.5-3 mg/day | 5-15 mg/day |
| Weight Gain | Significant (~2.7 kg/8 weeks) | Significant but may be slightly less |
| Prolactin Elevation | High (gynecomastia, galactorrhea risk) | Low (may actually lower prolactin) |
| Sedation | Common, often dose-limiting | Less pronounced |
| Akathisia | Less common | More common (can mimic behavioral worsening) |
| Other Key Side Effects | Drooling, EPS | Nausea, vomiting |
Metabolic Monitoring Protocol
Rigorous metabolic monitoring is mandatory for any child on an atypical antipsychotic. At baseline, height, weight, BMI, waist circumference, fasting glucose, fasting lipid panel, and HbA1c should be obtained. Weight and BMI should be rechecked at 4 and 8 weeks, with fasting glucose and lipids added at 8 and 12 weeks. Blood pressure should be added at 12 weeks. Quarterly monitoring of weight, BMI, and blood pressure follows. Fasting glucose, lipid panel, and HbA1c should be checked annually. Prolactin levels should be obtained if symptoms suggest elevation. The AIMS (Abnormal Involuntary Movement Scale) should be performed at baseline and every 6 months to screen for tardive dyskinesia.
Off-Label Pharmacotherapy for Comorbidities
ADHD Symptoms in ASD
Thirty to fifty percent of children with ASD have comorbid ADHD. Methylphenidate is effective but with smaller effect sizes (0.4-0.5) compared to ADHD without ASD (0.8-1.0) and higher rates of side effects including irritability, social withdrawal, emotional lability, and appetite loss. The RUPP methylphenidate trial (2005) showed a 49% response rate versus 16% for placebo, but 18% discontinued due to adverse effects. Amphetamines are less studied in this population. Guanfacine is effective for hyperactivity and impulsivity, generally well tolerated, and additionally helps with irritability and sleep, making it a reasonable first-line choice for ADHD symptoms in children with ASD. Atomoxetine has some evidence of modest benefit. The general approach is to start at lower doses than typical ADHD protocols, titrate more slowly, and monitor carefully for irritability and social withdrawal.
Anxiety in ASD
Anxiety is extremely common in ASD, affecting 40-60% of individuals, particularly those with higher cognitive functioning. Presentations may differ from typical anxiety and can include specific phobias, social anxiety, generalized worry, anxiety around routine changes, and sensory-driven anxiety. SSRIs are commonly used off-label, though RCT evidence specifically for ASD-plus-anxiety is limited. Fluoxetine, sertraline, and escitalopram are most commonly used, with starting doses that should be very low (such as fluoxetine 2.5-5 mg) due to increased sensitivity. Clinicians should watch carefully for activation, agitation, and disinhibition, which are more common in ASD. CBT adapted for ASD (such as the Facing Your Fears and Exploring Feelings programs) requires modifications to account for concrete thinking and the need for visual supports.
Repetitive Behaviors
SSRIs are commonly prescribed for repetitive and ritualistic behaviors in ASD, but the evidence is mixed. A large NIMH-funded RCT of citalopram for repetitive behaviors in children with ASD (King et al., 2009) was negative, showing no benefit over placebo with more adverse effects. While some clinicians report individual benefit, routine SSRI use for repetitive behaviors is not supported by current evidence. Behavioral interventions and environmental modifications remain the primary approach.
Self-Injurious Behavior (SIB)
Functional behavioral assessment is the essential first step, identifying whether the behavior serves an automatic/sensory, escape, attention, or tangible function. Underlying medical causes of pain or discomfort — dental pain, constipation, and GERD are common in ASD — must be addressed. When behavioral approaches are insufficient, pharmacotherapy options include atypical antipsychotics (risperidone or aripiprazole), N-acetylcysteine (which has preliminary evidence for irritability and repetitive behaviors), naltrexone (which has limited evidence for SIB, particularly in the context of intellectual disability, working through endogenous opioid blockade), and mood stabilizers if mood cycling is suspected.
Sleep Disturbance
Sleep problems affect 50-80% of children with ASD, with insomnia (difficulty falling asleep and maintaining sleep) being the most common complaint. Melatonin production may be abnormal in ASD, with levels either reduced or phase-shifted. Melatonin is the most studied pharmacological intervention for sleep in ASD, effective for reducing sleep onset latency and increasing total sleep time, dosed at 0.5-5 mg given 30-60 minutes before bedtime (starting low). Prolonged-release melatonin (PedPRM) has been specifically studied in ASD. Melatonin is generally safe but, as a supplement, is not FDA-regulated, so product quality varies. Behavioral sleep interventions — sleep hygiene, extinction-based approaches, and faded bedtime — should always be implemented alongside or before medication. Clonidine or guanfacine may help with sleep onset, especially when ADHD or hyperarousal is present. Antihistamines have limited evidence and raise concerns about next-day sedation and anticholinergic effects.
Aggression Not Responsive to First-Line
When risperidone or aripiprazole is inadequate for aggression, options include other atypical antipsychotics (olanzapine — effective but with the most metabolic side effects; quetiapine — limited evidence in ASD), mood stabilizers (valproate or lithium if mood instability is suspected), and combination strategies with careful monitoring.
Principles of Psychopharmacology in ASD
General Approach
The cardinal rule is "start low, go slow," targeting specific, measurable symptoms rather than "autism" broadly. Behavioral and environmental interventions should be tried first or concurrently. Clear target symptoms should be defined and tracked with standardized measures such as the ABC-Irritability subscale or the CGI. Only one medication should be changed at a time so effects can be attributed accurately. Regular reassessment of necessity should include periodic attempts at dose reduction or discontinuation. Polypharmacy should be avoided, with each medication having a clear rationale and documented target.
Special Considerations
Communication limitations in children with ASD may make it difficult for them to report side effects, making caregiver observation essential. GI sensitivity is common, and liquid or dissolving tablet formulations should be considered. Swallowing pills may be challenging and should be planned for. Some behaviors that appear psychiatric — aggression, self-injury — may have medical causes including pain, constipation, dental issues, or seizures, and these should always be considered before attributing behavioral changes to psychiatric comorbidity.
<image>A clinical algorithm for managing irritability and aggression in children with ASD. Start with functional behavioral assessment and rule out medical causes. First-line: behavioral intervention and environmental modification. If inadequate: FDA-approved atypical antipsychotics (risperidone or aripiprazole) with metabolic monitoring protocol. Second-line: switch antipsychotic, consider adjunctive mood stabilizer. Include a monitoring schedule panel showing when to check metabolic labs, prolactin, and movement disorders.</image>
<image>A side-by-side comparison infographic of risperidone vs. aripiprazole for irritability in ASD. Compare: FDA-approved age, typical dose range, mechanism of action, effect on irritability (response rates from key trials), weight gain risk, prolactin effects, sedation, akathisia risk, and other key side effects. Use a visual scorecard format to help guide clinical decision-making.</image>
<image>A comprehensive overview diagram showing the major comorbidities in ASD and their pharmacological management options. Central circle: ASD. Surrounding bubbles: irritability (risperidone, aripiprazole), ADHD (methylphenidate, guanfacine, atomoxetine), anxiety (SSRIs, CBT), sleep (melatonin, clonidine), SIB (behavioral, antipsychotics, naltrexone), repetitive behaviors (SSRIs -- limited evidence, behavioral). Include evidence strength ratings for each intervention.</image>
Clinical Pearls
No medication treats core ASD symptoms — all pharmacotherapy is for associated symptoms and comorbidities. Functional behavioral assessment should always precede or accompany medication trials for behavioral symptoms. Children with ASD are more sensitive to medication side effects, necessitating lower starting doses and slower titration. Risperidone and aripiprazole are the only FDA-approved medications for ASD-associated irritability; all other prescribing is off-label. Weight gain and metabolic syndrome are the most clinically significant long-term risks of atypical antipsychotics, and rigorous monitoring is mandatory. The citalopram RCT for repetitive behaviors in ASD was negative, meaning routine SSRI use for repetitive behaviors is not evidence-based. Melatonin is the most evidence-based pharmacological treatment for sleep onset insomnia in ASD. Always consider medical causes of behavioral change in ASD — pain, GI distress, and seizures — before attributing symptoms to psychiatric comorbidity. Stimulants work for ADHD in ASD but with smaller effect sizes and more side effects; guanfacine is a reasonable alternative first-line agent.
References
- Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. (2002). Risperidone in children with autism and serious behavioral problems. NEJM, 347(5), 314-321.
- Marcus, R.N. et al. (2009). Aripiprazole for irritability in children with ASD. JAACAP, 48(11), 1110-1119.
- RUPP Autism Network. (2005). Randomized controlled crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Archives of General Psychiatry, 62(11), 1266-1274.
- King, B.H. et al. (2009). Lack of efficacy of citalopram in children with ASD and high levels of repetitive behavior. Archives of General Psychiatry, 66(6), 583-590.
- Malow, B.A. et al. (2012). Melatonin for sleep in children with autism. JCSM, 8(2), 113-117.
- Hyman, S.L. et al. (2020). AAP Clinical Report on ASD. Pediatrics, 145(1), e20193447.
